Artificial intelligence is already reshaping how life sciences organizations approach quality, and senior leaders are now tasked with understanding both its value and its risks. In this session, Quality Assurance Manager Yijia Lee will explore how AI is being applied in quality today, where it is delivering measurable business impact, and how evolving expectations from the U.S. Food and Drug Administration are shaping adoption. The conversation will focus on what matters most at a strategic level—how to evaluate AI opportunities, align with regulatory direction, and establish the right governance, processes, and organizational readiness to move forward confidently and compliantly.